Print
|
Close
Aron E. Kefela MD
Northwest Georgia Oncology Centers, P.C.
www.ngoc.com
Education and Training
Specialty and Certification
Medical Oncology, Hematology / Board Certified
Clinical Trial Cancer Types
Breast Cancer, Cancer-Related Syndrome, Esophogeal Cancer, Leukemia, Myelodysplastic Syndromes (MDS), Solid Tumor, Stomach/ Gastric Cancer
Active Clinical Trial Sites in Georgia
Northwest Georgia Oncology Centers - Douglasville
6002 Professional Parkway
Suite 220
Douglasville, GA 30134
678-715-9690 (p)
678-581-7140 (f)
www.ngoc.com
driving directions
Clinical Trials
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Cancer Type: Breast Cancer
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Cancer Type: Breast Cancer
Connect® Myeloid Disease Registry
Cancer Type: Cancer-Related Syndrome
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Cancer Type: Esophogeal Cancer
Connect® Myeloid Disease Registry
Cancer Type: Leukemia
Connect® Myeloid Disease Registry
Cancer Type: Myelodysplastic Syndromes (MDS)
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Cancer Type: Solid Tumor
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Cancer Type: Stomach/ Gastric Cancer
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Cancer Type: Unknown Primary
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Cancer Type: Unknown Primary
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Cancer Type: Unknown Primary
Northwest Georgia Oncology Centers - Paulding
144 Bill Carruth Parkway
Suite 3100
Hiram, GA 30141
678-363-1940 (p)
678-581-7110 (f)
www.ngoc.com
driving directions
Clinical Trials
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Cancer Type: Breast Cancer
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Cancer Type: Breast Cancer
Connect® Myeloid Disease Registry
Cancer Type: Cancer-Related Syndrome
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Cancer Type: Esophogeal Cancer
Connect® Myeloid Disease Registry
Cancer Type: Leukemia
Connect® Myeloid Disease Registry
Cancer Type: Myelodysplastic Syndromes (MDS)
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Cancer Type: Solid Tumor
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Cancer Type: Stomach/ Gastric Cancer
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Cancer Type: Unknown Primary
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Cancer Type: Unknown Primary
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Cancer Type: Unknown Primary
Active Clinical Trial Site Locations:
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please
contact us
.